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Summary
Background Heterogeneity is a major obstacle to developing effective treatments for patients with primary Sjögren’s 
syndrome. We aimed to develop a robust method for stratification, exploiting heterogeneity in patient-reported 
symptoms, and to relate these differences to pathobiology and therapeutic response.
Methods We did hierarchical cluster analysis using five common symptoms associated with primary Sjögren’s 
syndrome (pain, fatigue, dryness, anxiety, and depression), followed by multinomial logistic regression to identify 
subgroups in the UK Primary Sjögren’s Syndrome Registry (UKPSSR). We assessed clinical and biological differences 
between these subgroups, including transcriptional differences in peripheral blood. Patients from two independent 
validation cohorts in Norway and France were used to confirm patient stratification. Data from two phase 3 clinical 
trials were similarly stratified to assess the differences between subgroups in treatment response to hydroxychloroquine 
and rituximab.
Findings In the UKPSSR cohort (n=608), we identified four subgroups: Low symptom burden (LSB), high symptom 
burden (HSB), dryness dominant with fatigue (DDF), and pain dominant with fatigue (PDF). Significant differences 
in peripheral blood lymphocyte counts, anti-SSA and anti-SSB antibody positivity, as well as serum IgG, κ-free light 
chain, β2-microglobulin, and CXCL13 concentrations were observed between these subgroups, along with 
differentially expressed transcriptomic modules in peripheral blood. Similar findings were observed in the 
independent validation cohorts (n=396). Reanalysis of trial data stratifying patients into these subgroups suggested a 
treatment effect with hydroxychloroquine in the HSB subgroup and with rituximab in the DDF subgroup compared 
with placebo.
Interpretation Stratification on the basis of patient-reported symptoms of patients with primary Sjögren’s syndrome 
revealed distinct pathobiological endotypes with distinct responses to immunomodulatory treatments. Our data have 
important implications for clinical management, trial design, and therapeutic development. Similar stratification 
approaches might be useful for patients with other chronic immune-mediated diseases.
Funding UK Medical Research Council, British Sjogren’s Syndrome Association, French Ministry of Health, Arthritis 
Research UK, Foundation for Research in Rheumatology.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Primary Sjögren’s syndrome is a chronic, immune-
mediated inflammatory disease, characterised by ocular 
and oral dryness, musculoskeletal pain, profound fatigue, 
and an increased risk of lymphoma.1 Symptom severity 
varies greatly between individuals; some report unbearable 
pain and dryness, some report debilitating fatigue, but 
others report few symptoms.2 Co-existing clinical fea-
tures, such as anxiety and depression, are common and 
might modulate symptoms of primary Sjögren’s synd-
rome.3–5 No effective treatment exists, and the direct and 
indir ect health costs of primary Sjögren’s syndrome are 
substantial.6,7
A key challenge in the development of therapy for 
patients with primary Sjögren’s syndrome and many other 
immune-mediated inflammatory diseases is het erogeneity 
in clinical presentation, presumably driven by differences 
in underlying molecular pathology and responsible, at 
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least partially, for variable responses to therapies.8 Precision 
medicine refers to approaches to optimally define disease 
complexity and heterogeneity in order to tailor therapies to 
the appro priate patient populations and subpopulations. 
Although stratified medicine has had considerable suc-
cess in oncology, progress has been slower in immune-
mediated inflammatory diseases. Exist ing approaches 
attempt to identify disease subgroups on the basis of 
biological heterogeneity. Unlike cancers, in which the 
clinical endpoints and target tissue are well defined, 
the clinical manifestations of many immune-mediated 
inflammatory diseases, including primary Sjögren’s synd-
rome, are diverse. For some clinical mani festations, such 
as fatigue and pain, the target tissue is unclear. Conse-
quently, the relationship between dysreg ulated biological 
pathways and clinical symptoms is often difficult to 
establish. This heterogeneity also poses challenges in 
defining the appropriate clinical endpoints with which to 
measure effectiveness of therapies in clinical trials.9–11
In this study, we aimed to develop a symptom-based 
stratification approach and test its clinical, biological, and 
therapeutic significance.
Methods
Study design and participants
The UK Primary Sjögren’s Syndrome Registry (UKPSSR) 
is a national observational cohort of clinically well-
characterised patients with primary Sjögren’s syndrome, 
who fulfil the 2002 American European Consensus Group 
(AECG) classification criteria. Our study cohort was rec-
ruited between Aug 13, 2009 and Sept 27, 2011.12 The 
UKPSSR is an ongoing initiative. The UKPSSR holds 
detailed clinical and laboratory data that is collected pros-
pect ively, including patient-reported symptoms collected 
using standardised questionnaires.
Two independent European cohorts of patients with 
primary Sjögren’s syndrome were used as validation 
cohorts: the French Assessment of Systemic Signs and 
Evolution of Sjögren’s Syndrome (ASSESS) cohort, and 
the Norwegian Stavanger cohort. All patients met the 2002 
AECG criteria. The ASSESS cohort is a French cohort of 
patients recruited from 15 tertiary centres for autoimmune 
diseases between 2006 and 2009. The Stavanger cohort 
consists patients with primary Sjögren’s syndrome 
attending the Stavanger University Hospital (Norway), 
recruited between January, 2014, and August, 2016.
Baseline data that permitted our symptom-based 
stratifica tion were available from two randomised, placebo-
controlled trials of patients with primary Sjögren’s 
syndrome; the JOQUER trial,17 which investigated hydroxy-
 chlor oquine treatment, and the TRACTISS trial,18 which 
investi gated rituximab treatment. In the JOQUER trial, 
120 patients were randomly assigned (56 to hydroxy-
chloroquine and 64 to placebo), of whom 107 had 
base line data permitting symptom-based stratification. In 
the TRACTISS trial, 133 patients were randomly assigned 
(67 to rituximab and 66 to placebo), of whom 114 had 
baseline data permitting stratification.
Research ethics approval was granted by the UK North-
West Research Ethics Committee, and ethics committees 
in France (Bichat Teaching Hospital ethics committee) and 
Norway (Regional Ethics Committee West [2010/1455]). All 
participants provided informed consent.
Cluster discovery and model development
Symptom-based subgroups were first identified by 
hierarchical cluster analysis of the severity of five common 
symptoms of primary Sjögren’s syndrome (pain, fatigue, 
dryness, anxiety, and depression) in the UKPSSR cohort. 
Pain, fatigue, and dryness were measured using the 
Research in context
Evidence before this study
We searched MEDLINE for “Sjögren’s Syndrome”, including the 
terms “subsets”, “sub-groups”, “phenotypes”, and “endotypes”, 
filtering by “clinical trial”, “stratification”, and “immune-mediated 
inflammatory”. We also included major review articles from noted 
experts. We identified numerous reports of clinical heterogeneity, 
but weak evidence of biological subsets, mainly from small 
studies without external validation data and without clinically 
meaningful stratification.
Added value of this study
This study shows the existence of subgroups of patients with 
primary Sjögren’s syndrome with distinct profiles of symptom 
severity, clinical and biological profiles and therapeutic 
responses. Our symptom-based stratification approach not only 
represents a novel approach to stratified medicine but also an 
original strategy linking pathobiology to symptomatology, 
which is often poorly understood in clinical medicine.
Implications of all the available evidence
These data have important implications for future research, 
clinical practice, trial design, and therapeutic development. 
First, our data open new research avenues to further explore 
the pathogenesis of this disease. Second, our findings that 
different patient subgroups appear to respond differently 
to hydroxychloroquine and rituximab might help with 
personalised care of these patients. Furthermore, our 
symptom-based stratification enables stratification and 
clinical management plans to be made quickly, without the 
requirement for sophisticated laboratory analyses. 
Finally, our proposed stratification tool might have a 
substantial effect on clinical trial design, in terms of patient 
stratification and corresponding clinical study endpoints, 
improving efficiency and reducing the cost of drug 
development.
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EULAR Sjogren’s Syndrome Patient Reported Index 
(ESSPRI),13 anxiety and depression using the Hospital 
Anxiety and Depression Scale (HADS).14 The ESSPRI and 
HADS have been extensively validated with excellent 
internal consistency and test-retest reliability.13,14
Clustering analysis is sensitive to sample size15 and 
both external validation cohorts were small compared 
with the UKPSSR. Therefore, we used a simple algorithm 
(the Newcastle Sjögren’s Stratification Tool [NSST]) 
permitting classification of individual patients into our 
four candidate subgroups in the clinic. A multinom-
ial log istic regression model was developed, predicting 
cluster membership on the basis of the same five patient 
reported symptoms using a training subset of two-thirds 
of all patients (selected randomly); the remaining third 
was used for testing of the model. The receiver operating 
characteristic curves for the training and test datasets had 
an area under the curve of greater than 0·95 for all 
symptom-based subgroups (appendix p 8), indicating 
that the NSST stratification algorithm faithfully repli-
cates the initial clustering model. The NSST was used 
to assign patients from the independent cohorts to 
symptom-based sub groups for validation of the key clini-
cal and biological findings. The NSST is available to 
Figure 1: Patient reported symptom scores for each cluster
(A) Dendogram and symptom heatmap shows results of the cluster analysis of patient symptom scores from the ESSPRI and HADS scores for pain, fatigue, dryness, 
anxiety, and depression. The symptoms are colour-coded in the heatmap at the base of the dendrogram: teal is low, white is intermediate, and brown represents a high 
symptom score. (B) Median (IQR) patient reported symptom scores within each cluster. ESSPRI=the EULAR Sjogren’s Syndrome Patient Reported Index. HADS=Hospital 
Anxiety and Depression Scale. 
A
B
Patient-reported symptoms
ESSPRI-Dryness (0–10)
ESSPRI-Fatigue (0–10)
ESSPRI-Pain (0–10)
HADS-Anxiety (0–21)
HADS-Depression (0–21)
3 (2–4)
2 (1–3)
1 (0–2)
5 (3–7)
2 (1–4)
 7 (6–8)
 7 (6–9)
 7 (5–8)
 14 (11–15)
 11 (9–13)
 8 (7–9)
 6 (4–7)
 2 (0·25–3)
 5 (3–8)
 4 (2–6·75)
 6 (4–7)
 6 (5–8)
 6 (5–8)
 7 (5–9)
 5 (3–7)
Low symptom burden
High symptom burdenLow symptom burden Pain dominant with fatigue
UKPSSR cohort
(n=608)
Dryness dominant with 
fatigue
High symptom burden Dryness dominant with fatigue Pain dominant with fatigue
Min
Max
Low symptom
burden cluster
High symptom
burden cluster
Dryness dominant 
with fatigue cluster
Pain dominant with
fatigue cluster
Depression
Anxiety
Pain
Fatigue
Dryness
Articles
e88 www.thelancet.com/rheumatology   Vol 1   October 2019
academic and non-commercial researchers as an Excel 
macro algorithm.
Endotype discovery
All clinical and laboratory (including transcriptomic) 
parameters, as well as peripheral blood samples, for 
analy ses in this study for all three cohorts were obtained 
at the time of recruitment and entry to the respective 
cohorts.
Ocular dryness was assessed using Schirmer’s test and 
oral dryness using unstimulated salivary flow (USF). 
Systemic disease activity was measured using the EULAR 
Sjögren’s Syndrome Disease Activity Index (ESSDAI).13 
Other clinical and demographic parameters assessed are 
listed in the appendix (p 3-4).
Data on serum β2-microglobulin, and κ-free and λ-free 
light-chains (FLCs) were available for 596 UKPSSR 
patients, and CXCL13 data were available for 112 patients. 
Data on these serum proteins were available from the 
ASSESS cohort. Serum protein data were log-transformed 
before ANOVA testing for significant differ ences across 
symptom-based subgroups (appendix p 6).
Whole-blood transcriptomic data for 196 UKPSSR and 
312 ASSESS patients were available (appendix p 6). Data 
were mean centred, and module activity scores calculated 
according to the Chaussabel method.16 These transcripto-
mic modular data were used for discriminant analysis 
with the wide linear method maximising discrim ina tion 
between symptom-based subgroups and estim ating 
canonical scores for each patient by singular value decom -
position of the standardised data. We also investigated dif-
fer ences in expression of individual annotated Chaussabel 
modules between the symptom-based subgroups using 
ANOVA across subgroups and cohorts.
Statistical analysis
A schematic representation of the cohorts and analysis 
stages is shown in the appendix (p 7). All statistical tests 
and graphical rendering were done using the R statistical 
package and SAS JMP statistical data visualisation 
software (version 14). Summary data—including medians 
and quartiles, or percentages for counts data—are pres-
ented, and Kruskal-Wallis analysis of ranks, or ANOVA of 
rank or log-transformed data, were used to identify 
potential differences between symptom-based sub groups. 
For the comparison of cohorts, linear models were 
constructed including terms for subgroups and cohort 
and their interaction. For the JOQUER and TRACTISS 
trials, we reanalysed trial outcomes including terms for 
subgroup and treatment and their interaction.
Role of the funding source
The funders and sponsors of the study had no role in 
study design, data collection, data analysis, data inter-
pretation, or writing of the report. WFN, DWL, and JRT 
had full access to all the data in the study. WFN and JDI 
had the final responsibility for the decision to submit for 
publication.
Results
Clinical and demographic characteristics of the UKPSSR 
cohort (n=608), and the ASSESS (n=334) and Stavanger 
(n=62) validation cohorts, are summarised in the 
appendix (p 14). Patients were predominantly female and 
white. There were no significant differences in age, med-
ian ESSDAI, or ESSPRI scores between the three cohorts. 
The disease duration was longer in the Stavanger cohort 
than in the UKPSSR and ASSESS cohorts. We found 
small but statistically significant differences in body-mass 
index (BMI) between the three cohorts (appendix p 14).
Low symptom 
burden
High symptom 
burden
Dryness 
dominant with 
fatigue
Pain dominant 
with fatigue
p value
Unstimulated salivary flow, ml/15 min
UKPSSR 0·4 (0·0–1·05) 0·2 (0·0–1·0) 0·1 (0·0–0·8) 0·3 (0·0–1·2) 0·0097
ASSESS 0·3 (0·1–1·7) 0·4 (0·1–2·2) 0·0 (0·0–0·2) 0·2 (0·1–1·5) <0·0001
Stavanger 1·7 (0·4–2·2) 0·8 (0·1–2·5) 0·2 (0·0–0·7) 0·9 (0·0–1·7) 0·12
Combined 0·3 (0·1–1·5) 0·3 (0·0–1·3) 0·1 (0·0–0·2) 0·3 (0·0–1·4) <0·0001
Schirmer’s Test (mm/5 mins)
UKPSSR 3·0 (0·0–6·8) 3·0 (0·5–10·5) 2·0 (0·0–6·5) 4·0 (0·1–10·5) 0·014
ASSESS 5·3 (2·0–15·0) 5·8 (2·3–14·4) 7·0 (0·0–13) 7·5 (3·5–15) 0·26
Stavanger 7·0 (2·5–13·6) 6·8 (2·8–23·1) 1·5 (0·0–4·5) 5·5 (2·5–14·5) 0·024
Combined 3·9 (0·5–9·0) 5·0 (1·0–12·5) 2·3 (0.0–7·1) 5·0 (2.0–12·5) <0·0001
Lymphocytes, ×109/L
UKPSSR 1·2 (1.0–1·6) 1·5 (1·2–1·8) 1·3 (1.0–1·7) 1·3 (1·0–1·7) <0·0001
ASSESS 1·3 (1.0–1·8) 1·5 (1·1–1·7) 1·2 (1.0–1·6) 1·5 (1·1–1·8) 0·025
Stavanger 1·4 (0·7–1·7) 1·9 (1·6–2·4) 1·2 (0·9–1·4) 1·8 (1·3–2.0) 0·030
Combined 1·3 (1.0–1·6) 1·5 (1·2–1·7) 1·2 (1.0–1·7) 1·4 (1·1–1·8) <0·0001
Serum IgG, mg/dL
UKPSSR 18·0 (14·5–22·9) 14·1 (11·1–18·2) 16·6 (13.0–20·9) 14·4 (11·1–19·5) <0·0001
ASSESS 15·0 (12·3–18·7) 12·8 (10·7–16·7) 15·2 (11·1–20·6) 12·5 (9·8–16·1) 0·0028
Stavanger 14·0 (10·7–16.0) 11·1 (9·3–11·9) 14·9 (12·4–18) 11·7 (10·0–13·1) 0·0054
Combined 16·6 (13·2–21·5) 13·4 (10·7–17.0) 16·0 (12·4–20·3) 13·1 (10·2–17·7) <0·0001
SSA or SSB positive, or both, n/N (%)
UKPSSR 111/119 (93·3%) 128/147 (87·0%) 113/120 (94·2%) 189/222 (85·1%) 0·024
ASSESS 45/64 (70·0%) 50/85 (58·8%) 32/43 (74·4%) 76/141 (53·9%) 0·049
Stavanger 9/10 (90·0%) 3/5 (60·0%) 18/18 (100%) 17/29 (58·6%) 0·0018
Combined 165/193 (85·5%) 181/237 (76·4%) 163/181 (90·0%) 282/392 (71·9%) <0·0001
Patients, n (%)
UKPSSR 
(N=608)
119 (19·6%) 147 (24·2%) 120 (19·7%) 222 (36·5%) ··
ASSESS 
(N=334)
64 (19·2%) 85 (25·4%) 43 (12·9%) 142 (42·5%) ··
Stavanger 
(N=62)
10 (16·1%) 5 (8·1%) 18 (29·0%) 29 (46·8%) ··
Combined 
(N=1004)
193 (19·2%) 237 (23·6%) 181 (18·0%) 393 (39·1%) ··
Data are median (IQR), unless otherwise indicated. The combined probability is for the pooled analysis across all 
three cohorts after rank transformation and ANOVA including subgroup, cohort, and subgroup by cohort interaction. For 
p values corrected for multiple comparisons see appendix (p 15). UKPSSR=UK Primary Sjögren’s Syndrome Registry. 
ASSESS=Assessment of Systemic Signs and Evolution of Sjögren’s Syndrome.
Table 1: Objective parameters between subgroups
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An unsupervised hierarchical cluster analysis using 
the patient-reported symptoms of pain, fatigue, dryness, 
anxiety, and depression identified four key clusters 
(figure 1). These clusters were low symptom burden (LSB), 
high symptom burden (HSB), dryness dominant with 
fatigue (DDF), and pain dominant with fatigue (PDF).
The LSB cluster was characterised by low scores on all 
five symptoms whereas the HSB cluster scored highly on 
all five symptoms. The key features of the DDF cluster 
were high dryness and fatigue scores, but low anxiety 
and depression scores. The PDF cluster was characterised 
by high pain and fatigue scores but low anxiety and 
depression scores. We then used multinomial logistic 
regression to develop a stratification tool on the basis of 
observed cluster membership, for stratification of other 
patients with primary Sjögren’s syndrome into these 
four symptom-based subgroups.
We found no statistically significant differences in age, 
sex, disease duration, and ESSDAI, nor in prescription of 
hydroxychloroquine, prednisolone, or other immuno-
suppressive drugs, between different subgroups.
In the UKPSSR cohort we found significant differences 
in salivary flow; Schirmer’s test, serum IgG, lympho cyte 
counts, and the prevalence of anti-SSA and anti-SSB 
antibody positivity between these four subgroups (table 1). 
The DDF subgroup showed the lowest values on objective 
measures of glandular function. The LSB subgroup had 
the highest serum IgG levels and low lymphocyte counts. 
Anti-SSA and anti-SSB antibody positivity was higher in 
the DDF and LSB subgroups than in the HSB and PDF 
subgroups (table 1).
These clinical differences observed in the UKPSSR 
were assessed in two independent cohorts using the 
NSST. We found statistically significant differences in the 
expected direction for IgG, lymphocyte counts, anti-SSA 
anti-SSB positivity, and consistent differences in objective 
measures of oral and ocular glandular function (table 1).
CXCL13, β2-microglobulin, and κ-FLC concentrations 
differed significantly across subgroups in the UKPSSR 
cohort, with the highest concentrations occurring in the 
DDF subgroup (table 2). The DDF subgroup had the 
highest prevalence of lymphoma within the UKPSSR 
cohort (table 2). Sub group differences in serum levels of 
these proteins were comparable in the ASSESS cohort 
and followed a similar pattern to those in the UKPSSR 
cohort (table 2).
Discriminant analysis was done using the available 
transcriptomics data from the UKPSSR and ASSESS 
cohorts. The appendix (p 10) shows the three-dimensional 
positions of individual patients’ overall transcriptomic 
modular profiles in canonical space based upon the 
first three canonical variables (video). The overall trans-
criptomic profiles of the four subgroups were consistent 
between these two independent cohorts.
At the level of individual transcriptomic modules, we 
found statistically significant differences in 31 (31%) of 
100 annotated scores for Chaussabel transcriptomic 
module activity between the subgroups (figure 2). Scores 
for interferon (IFN) module activity were sig nificantly 
higher in the LSB and DDF subgroups than in the HSB 
and PDF subgroups. The LSB subgroup had the highest 
activity score for most modules except the mature B-cell 
modules. By contrast, the DDF sub group had the lowest 
score for most modules apart from the IFN and mature 
B-cell modules, which was highest in the DDF subgroup. 
The differences in the mature B-cell modules are largely 
driven by the altered express ion of genes associated with 
B cell signalling, germ inal centres, lymphoproliferative 
disease, and oxidative stress.
When we attempted to use ESSDAI to stratify patients 
according to their systemic disease activity, the stratifica-
tion based on patient reported symptoms outperformed 
the ESSDAI-based stratifi cation, giving better goodness-
of-fit and identifying more Chaussabel modular differ-
ences (appendix pp 4–5).
To assess the therapeutic significance of our stratifica tion 
strategy, we used the NSST algorithm to stratify patients 
from the JOQUER and TRACTISS trials. In the TRACTISS 
trial, because rituximab is known to target B cells, we 
hypothesised that the DDF subgroup was more likely to 
respond to rituximab than were the other subgroups 
because the DDF subgroup had the high est mature B-cell 
transcriptomic modular score, serum κ-FLC and λ-FLC, 
β2-microglobulin, and CXCL13 concentrations.
Consistent with the original studies, we found no 
statistically significant overall (ie, non-stratified) treat ment 
Low symptom 
burden
High symptom 
burden
Dryness 
dominant with 
fatigue
Pain 
dominant 
with fatigue
p value
κ-free light chains (mg/L)
UKPSSR 3·20 (0·52) 3·06 (0·52) 3·25 (0·6) 3·08 (0·47) 0·0336
ASSESS 2·80 (0·55) 2·72 (0·59) 2·89 (0·64) 2·59 (0·56) 0·0106
λ-free light chains (mg/L)
UKPSSR 2·94  (0·45) 2·86 (0·47) 3·00 (0·50) 2·86 (0·44) 0·0485
ASSESS 2·75 (0·52) 2·69 (0·51) 2·78 (0·65) 2·63 (0·52) 0·3375
β2-microglobulin (mg/L)
UKPSSR 1·34 (0·22) 1·30 (0·24) 1·38 (0·27) 1·32 (0·24) 0·0336
ASSESS 1·20  (0·22) 1·16 (0·19) 1·25 (0·24) 1·12 (0·20) 0·0031
CXCL13 (pg/ml)
UKPSSR* 4·86 (0·53) 4·97 (0·63) 5·33 (0·68) 5·00 (0·70) 0·040
ASSESS 4·74 (1·00) 4·93 (1·12) 4·98 (0·78) 4·48 (0·83) 0·0010
Lymphoma prevalence, n/N (%)
UKPSSR 2/119 (1·7%) 12/208 (5·8%) 13/120 (10·8%) 6/222 (2·7%) 0·0113
Data are mean (standard error), unless otherwise indicated. Data were available for 596 patients from the UKPSSR and 
334 patients from the ASSESS cohorts. p values are for analysis of variance of log-transformed protein data testing 
separately for differences between subgroups within the two cohorts. Percentages are shown for lymphoma 
prevalence from the UKPSSR. The p value for lymphoma prevalence is for an exact permutation test for differences in 
prevalence between the subgroups. UKPSSR=UK Primary Sjögren’s Syndrome Registry. ASSESS=Assessment of 
Systemic Signs and Evolution of Sjögren’s Syndrome. *CXCL13 was measured for a subset of 112 patients in the 
UKPSSR only (appendix p 16).
Table 2: Serum protein analysis
See Online for video
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effect for the change in ESSPRI scores in either study 
group. However, we found treatment–subgroup inter-
actions in both studies (figure 3). Individual con trasts 
were formed to estimate treatment differences within 
each subgroup (figure 3). In the JOQUER trial, we found a 
clinically significant reduction (ie, improve ment) in 
ESSPRI scores (ie, >1)19 for the HSB subgroup (p=0·01). 
In the TRACTISS trial, we found no statistically signifi-
cant effects on ESSPRI scores, but as hypothesised, 
patients in the DDF subgroup receiving rituximab had 
significantly higher USF (p=0·04) and stimulated salivary 
flow (figure 3, p=0·03) than did patients in the DDF 
subgroup who were on placebo at week 48. No treatment 
effect was observed for other subgroups in either trial.
Discussion
Using patient reported symptoms, we identified four sub -
groups of patients with primary Sjögren’s syndrome with 
distinct clinical and biological profiles, suggesting that 
these are true endotypes,19 and these patients are likely to 
differ in their response to targeted therapies. Our data 
support the use of these subgroups in dissecting the 
biological basis of this complex disease and its associated 
debilitating symptoms, informing clinical manage-
ment and the design of future clinical trials of patients 
with primary Sjögren’s syndrome. To our knowledge, 
this is the first report showing distinct subsets of an 
immune-mediated inflammatory disease and linking 
clinical and patho biological heterogeneity, with direct 
clinical implications.
Conventionally, patients with primary Sjögren’s synd-
rome are thought to consist of two subtypes—those 
with predominantly glandular symptoms and those with 
extra-glandular (systemic) manifestations. However, many 
patients do not fit neatly into these subtypes and no con-
sensus criteria exist for such classification. 
Our stratification approach centred on identifying, 
characterising, and validating clinical subgroups before 
attempting to assess underlying pathobiological hetero-
geneity. Our rationale was that a clinical phenotype in an 
immune-mediated inflammatory disease is likely to be 
underpinned by networks of dysregulated biological path-
ways rather than one or a few pathways. Consequently, 
without initial careful clinical characterisation, even the 
most advanced methods for analysing high-dimensional 
data face a daunting task.20,21
For our initial exploratory clustering analysis, alongside 
the cardinal primary Sjögren’s syndrome symptoms (pain, 
fatigue, dryness),19 anxiety and depression were included 
because these symptoms are common in patients with 
primary Sjögren’s syndrome, affect overall symptom 
burden (particularly pain and fatigue), and are relevant for 
clinical trial outcomes.3,5 Furthermore, immune-mediated 
mechanisms have been implicated in depression,22 raising 
Figure 2: Chaussabel module activity scores
Chaussabel module activity scores adjusting for batch differences for the UKPSSR and ASSESS transcriptomics datasets centred on the mean for each module. 
Shown are the top 31 modules with significant differences between subgroups in the UKPSSR and ASSESS cohorts. Negative values imply inhibition and positive 
values imply activation. The error bars represent 95% CIs. For example, the first module is activated in patients in the dryness dominant with fatigue and low 
symptom burden subgroups, but inhibited in patients in the high symptom burden. and pain dominant with fatigue subgroups. Of particular interest are the 
modules IFN Response, mature B cells, and T cells (highlighted red). Unadjusted p values were used in this analysis. Details of the modules including the adjusted 
p values are listed in the appendix (p 17). IFN=interferon.
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the possibility that depression might be a manifestation of 
the pathobiology of primary Sjögren’s syndrome. Patient-
reported data play an increasingly recognised role in 
clinical trials, therapeutic licensing, and health-care policy 
decisions, and are key to capturing quality of life and 
health economic outcomes.23 Although some researchers 
might have concerns over the subjectivity and reliability of 
patient reported symptoms, the instruments we used 
to measure symptom severity have been shown to 
have excellent internal consistency and test-retest relia-
bility.13,14 Furthermore, the symptom profiles between the 
four subgroups that we describe differ markedly from 
one another and therefore the risk of misclassification 
due to variability in self-reported assessments is small. 
Importantly, had our data not been robust, validation in 
two independent cohorts would have been highly unlikely. 
From a clinical perspective, our approach allows patient 
stratification at the point of care. More importantly, 
symptoms are the key driver for patients with primary 
Sjögren’s syndrome seeking medical help and hence the 
use of health-care resources.
The LSB and DDF subgroups shared many objectively 
meas ured laboratory features, including reduced lym pho -
cyte counts and increased IgG concentrations, and were 
more likely to be anti-SSA and anti-SSB positive than were 
the HSB and PDF subgroups. However, as anticipated, 
Figure 3: Reanalysis of two clinical trials using symptom-based subgroups
(A) ESSPRI scores for each subgroup for patients in placebo and HCQ groups in the JOQUER trial.17 Box plots show the median ESSPRI scores, quartiles, and ranges for 
placebo and hydroxychloroquine for LSB, HSB, DDF, and PDF subgroups. The step break indicates the mean ESSPRI scores of the placebo and hydroxychloroquine 
treatments for each subgroup. Although we found no overall treatment effect, we found a significant treatment by subgroup interaction. This consistency test is 
statistically significant (p=0·036). The p values shown are for the contrast within each subgroup. (B) Stimulated salivary flow for each subgroup for patients in the 
placebo and rituximab groups of the TRACTISS trial.18 Box plots of log transformed data show the median SSF and ranges for placebo and rituximab treatments for 
each subgroup. Data are shown for the LSB subgroup; however, statistical analysis was not done because of insufficient data in this stratum. Although the figures 
show group values at the end of the trial, the probability values refer to the statistical analysis on changes from baseline as per the original clinical protocols. LSB=low 
symptom burden. HSB=high symptom burden. DDF=dryness dominant with fatigue. PDF=pain dominant with fatigue. SSF=stimulated salivary flow.
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the DDF subgroup had the poorest objectively measured 
glandular function. Furthermore, we found differences in 
the transcriptomic modular profiles between the LSB and 
DDF subgroups. Lymphoma prevalence was also highest 
in the DDF subgroup in the UKPSSR cohort. Consistently, 
the DDF subgroup had the highest serum concentrations 
of CXCL13 (which has been linked to lymphoma in 
patients with primary Sjögren’s syndrome24), the highest 
levels of β2-microglobulin (a prognostic marker of poor 
outcomes in malignant lymphoma25), and altered express-
ion of genes associated with B-cell signalling, germinal 
centres, lymphoproliferative disease, and oxi dative stress. 
Long-term studies, however, are needed to substantiate 
the association of the DDF subgroup with lymphoma 
development. That the LSB subgroup had the highest 
levels of IFN and T cell transcriptomic modular activities 
might seem counterintuitive. However, our findings are 
consistent with the results of a study by Bodewes and 
colleagues, showing that pain scores are reduced in 
patients with primary Sjögren’s syndrome that show 
systemic IFN activity.26 Similarly, in a model of IFN-α 
induced fatigue, Russell and colleagues showed that 
persist ent fatigue is not associated with peripheral 
immune activation.27 Collectively, these data highlight our 
poor understanding of the mechanisms underpinning 
the symptomatology of primary Sjögren’s syndrome 
and challenge the simple notion of peripheral immune 
activation being responsible for the symptoms.
We found no significant differences between the PDF 
and HSB subgroups in objectively measured laboratory 
parameters. The overall transcriptomic profiles differed 
considerably between these groups, however, despite sim-
ilarities in the level of transcription of individual modules. 
Furthermore, clinical responses to hydroxy chloro quine 
appeared to differ between these groups. Further char-
acterisation of the pathobiology of these two subgroups is 
warranted, including non-immunological mechanisms.
Whole-blood transcriptomics might not correlate with 
protein expression in either blood or target tissue.28,29 
However, in related conditions, such as systemic lupus 
erythematosus, transcriptomic changes in blood are sim-
ilar to those in target organs such as the kidney.29 Also, 
mass cytometry data have shown that cellular com-
ponents in blood correlate with clinical parameters 
and glandular inflammation in patients with primary 
Sjögren’s syndrome.30 Because the target organ for many 
of the debilitating symptoms (such as pain and fatigue) 
of primary Sjögren’s syndrome is unknown, blood is a 
reasonable starting point in the search for biological 
differences between symptom-based subgroups.
Although alternative transcriptomics analytical app-
roaches, including Kyoto Encyclopedia of Genes and 
Genomes, BioCarta, and Ingenuity Pathway Analysis 
exist, gene sets from these databases derive from mul-
tiple data sources and tissue types and might not be rele-
vant for whole-blood analyses. Furthermore, the same 
gene might appear in multiple pathways and gene sets, 
making inferring which pathways are disturbed difficult. 
Instead, we used Chaussabel modules to explore the 
patho biological differences between groups. These mod-
ules were developed in a data-driven manner, speci fically 
for the characterisation of transcriptomic profiles in 
human whole-blood samples, such that each gene set 
(module) is mutually exclusive.
From a therapeutic perspective, the biological differ-
ences between the four subgroups might inform future 
stratified approaches. For instance, therapies targeting 
T cells might be effective for the LSB subgroup but not 
DDF subgroup, whereas treatments targeting CXCL13 or 
B cells might be the preferred strategy for the DDF 
subgroup. On the other hand, therapies targeting inter-
feron pathways could be more effective for DDF and 
LSB subgroups, although careful selection of clinical 
endpoints to measure thera peutic responses for these 
subgroups is crucial, par ticularly for the LSB subgroup, in 
which symptoms were minimal.
Our data also support close consideration of these 
symp tom-based subgroups when designing future clini-
cal trials of primary Sjögren’s syndrome. For example, 
results from the JOQUER and TRACTISS trials were 
initially dis appointing. However, reanalysis of the data 
stratify ing by these subgroups indicated treatment effects 
in response to hydroxychloroquine for the HSB subgroup 
and to rituximab for the DDF subgroup. We expected to 
find treatment effects in response to rituximab for the 
DDF subgroup, given that the DDF subgroup had the 
highest mature B-cell modular scores. The original trials 
were not powered for a stratified analysis, however, and 
further validation of these findings is needed. Our data 
also suggest that the choice of primary endpoint in future 
trials might differ between symptom-based subgroups 
and will be crucial in assessing the outcome of inter-
ventions. Additionally, although data on anxiety and 
depression have not been routinely collected in clinical 
trials of primary Sjögren’s syndrome (and indeed in most 
patient cohorts), we would like to see our stratification 
algorithm incorporated into future trial designs. We have 
not presented longitudinal data but the study of long-
term outcomes and stability of these subgroups of 
patients with primary Sjögren’s syndrome is ongoing. 
Our preliminary analysis suggests that the subgroups are 
largely stable for 4–5 years.
This study is not without limitations. Although cluster-
ing analysis is a useful exploratory tool, the method 
is sensitive to the choice of clustering method and 
assessment metrics, and there is no consensus on the 
opti mal approach. In this study, we adopted a team 
approach, involving biostatisticians, bioinfor maticians, 
data scientists, and clinicians in decision-making. In 
select ing the clustering method to use for the subsequent 
dev elop ment of a stratification tool, we considered clinical 
experience as well as statistical assess ment of cluster 
metrics (appendix pp 1–3). We believe that our choice to 
use hierarchical clustering analysis was vindicated by the 
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successful validation against two external, independent 
cohorts. A small subgroup possibly exists within the 
patients in the PDF subgroup with very high pain, fatigue, 
and dryness score (appendix p 2), and a future study to 
investigate this possibility might be worthwhile. A further 
limitation of our work is that, although we have pain-
stakingly combined data from multiple platforms, cohorts, 
and trials, none of these studies was designed with strati-
fication as the primary objective. In particular, the trials 
were not powered for a stratified analysis. Further more, 
although the transcript omics and cytokine data are illum-
in ating, these data were not collected to address biomarker 
selection or stratification objectives.
We do not exclude other stratification strategies. How-
ever, our data show that symptom-based stratification is a 
robust and clinically meaningful approach, addressing the 
clinical heterogeneity of patient experience and reflect-
ing differences in pathobiological profiles and therapeutic 
responses.
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